This item is in: Biomedicine > Nanoscience and technology in medicine

Nanoparticulate drug delivery: Perspectives on the transition from laboratory to market

V Patravale, Institute of Chemical Technology, India, P Dandekar and R Jain, Institute of Chemical Technology, India

Woodhead Publishing Series in Biomedicine No. 17

 - discusses the issues surrounding nanoparticulate products, based on personal experience of their formulation
 - provides an overview of new application areas, including RNA interference
 - outlines the pros and cons of nanoparticulate products, and discusses how these may influence their route into the commercial sector
 - provides information relevant to both the industrial and the academic sectors

Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic window of existing drug molecules. Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems from the laboratory into a commercially viable sector. The first chapters of the book provide an overview of the use and characterization of nanoparticulate systems as drug carriers, including the assessment of their morphology, sterility and potential toxicity. In the latter part of the book, chapters cover nanotoxicology, regulatory aspect and clinical trials, ending with an overview of several case studies and a look towards future developments.

ISBN 1 907568 98 0
ISBN-13: 978 1 907568 98 5
October 2012
244 pages  234 x 156mm  hardback  
£120.00 / US$205.00 / €145.00

Usually dispatched within 24 hours

An e-book version of this title is available to purchase as part of a Collection or Pick n Mix or by Chapter. Visit Woodhead Publishing Online

About the authors

Vandana Patravale is a Professor of Pharmaceutics at the Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India. Her research group is actively involved in the design and development of colloidal drug delivery systems for various routes including oral, topical, transdermal, nasal and parenteral.

Prajakta Dandekar is the first female Indian scientist to be award the European Respiratory Society – Marie Curie Joint Postdoctoral Fellowship and is currently a guest scientist at the Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany. Her research interests include the design of polymeric nanoparticles of novel polymers for application in siRNA delivery and gene therapy

Ratnesh Jain has been awarded the Alexander von Humboldt Postdoctoral Fellowship by the AvH Foundation and is currently a guest scientist at the Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany. His research interests include design of nanoparticles of commercial cationic polymers for application in siRNA delivery and gene therapy.

Titles which may also be of interest:
Nanoparticle-based approaches to targeting drugs for severe diseases

Contents

Nanoparticulate systems as drug carriers: the need
 - Introduction: nanoparticles for drug delivery
 - Need: solubility, bioavailability, targeting and more
 - Specifi c nanoparticulate strategies for overcoming solubility and bioavailability limitations
 - References

Nanoparticles as drug carriers
 - Nanoparticles as drug carriers: the scope
 - Nanoparticles as drug delivery carriers
 - Application areas for nanoparticulate drug delivery systems
 - Routes of administration of nanoparticulate drug delivery systems
 - Conclusion
 - References

Characterization techniques for nanoparticulate carriers
 - Need and challenges for characterisation techniques of nanoparticulate drug carriers
 - Measuring the size of nanoparticles
 - Zeta potential measurement
 - Characterizing the morphology of the nanoparticles
 - Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles
 - Toxicity evaluation of nanoparticles
 - Evaluating immunological potential of nanoparticles
 - References

Nanotoxicology: evaluating toxicity potential of drug-nanoparticles
 - Nanotoxicology: need towards developing safe and sustainable drug delivery systems
 - In vitro assays for assessing toxicity of nanoparticles
 - In-vivo assays for assessing toxicity of nanoparticles
 - Genotoxicity evaluation
 - References

Regulatory aspects of nanoparticulate drug delivery systems
 - Nanoparticulate drug carriers: the regulatory facet
 - Issues associated with regulating nano-drug delivery systems
 - Current approaches for regulating pharmaceutical nanocarriers
 - References

Clinical trials and industrial aspects
 - Clinical trials of nanoparticulate drug delivery systems: successes and failures
 - Case studies: cancer
 - Case studies: other diseases
 - Nanoparticulate drug delivery: an industrial outlook
 - References

Case studies: nano-systems in the market
 - Case studies: performance and market approval
 - Are nano or conventional drug delivery systems a better choice? – a market overview
 - Future perspectives on nanoparticulate drug carriers
 - References